Geron shares are trading lower Tuesday after a Reuters report stated FDA staff reviewers raised multiple safety concerns over Geron's anemia drug, imetelstat. According to the report, FDA staff said the "clinical meaningfulness" of the clinical data was unclear and pointed to a high rate of low red blood cell counts in the study. FDA staff also reportedly said the study did not show a "disease-modifying effect."